Page 2 - Eric Broyles News Today : Breaking News, Live Updates & Top Stories | Vimarsana

U.S. Air Force F-16s Integrate With Italian Air Force F-35s During Agile Combat Employment Exercise U.S. Air Force F-16s Integrate With Italian Air Force F-35s During Agile Combat Employment Exercise Two U.S. Air Force F-16 Fighting Falcons assigned to the 31st Fighter Wing return from offensive counter air training with two Italian air force F-35 Lightning II assigned to the 32° Stormo during an Agile Combat Employment (ACE) exercise at Amendola Air Base, Italy, Feb. 17, 2021. (U.S. Air Force photo by Senior Airman Ericka A. Woolever) Agile Combat Employment exercise at Amendola Air Base, s...

The 555th and 510th Fighter Squadrons executed counter air training with the Italian air force 32 Stormo, Rome Air Squad Command. The 32 Stormo is the first European unit to acquire F-35A Lightning II aircraft. ,

The 555th and 510th Fighter Squadrons executed counter air training with the Italian air force 32 Stormo, Rome Air Squad Command. The 32 Stormo is the first European unit to acquire F-35A Lightning II aircraft. ,

F-16s from ‘Triple Nickel’ and 510th train with first European air unit to acquire F-35s February 19 Two U.S. Air Force F-16 Fighting Falcons assigned to the 31st Fighter Wing return from offensive counter air training with two Italian air force F-35 Lightning II assigned to the 32° Stormo during an Agile Combat Employment (ACE) exercise at Amendola Air Base, Italy, Feb. 17, 2021. (U.S. Air Force photo by Senior Airman Ericka A. Woolever) F-16 Fighting Falcons from the “Triple Nickel” and 510th fighter squadrons participated in a training exercise this week with the first air un...

Nanocan Therapeutics Corporation Announces Exclusive Global Licensing Agreement for Immunogenic Smart Radiotherapy Biomaterials Share Article Nanocan Therapeutics Corporation, an early-stage biotechnology company, today announced an exclusive global licensing agreement with Brigham and Women’s Hospital (Boston, MA), a teaching hospital of Harvard University’s Medical School, to develop and commercialize Immunogenic Smart Radiotherapy Biomaterials (iSRBs) for the treatment of pancreatic, lung, and cervical cancer. With our expertise in nanotechnology delivery, and grant investments from th...